19th week of 2014 patent applcation highlights part 39 |
Patent application number | Title | Published |
20140127163 | USE OF SLURP1 AS AN IMUNOMODULATORY MOLECULE IN THE OCULAR SURFACE - Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation. | 2014-05-08 |
20140127164 | BACTERIAL STRAINS BELONGING TO THE GENUS BIFIDOBACTERIUM FOR USE IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA - Selected bacterial strains belonging to the genus | 2014-05-08 |
20140127165 | ISOXAZOLINE INSECTICIDES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 2014-05-08 |
20140127166 | SUPPLEMENTION OF MATERNAL DIET - The use of probiotic bacteria in the manufacture of a composition for administration to a woman in at least the third trimester of pregnancy for prevention of gestational diabetes, normalizing plasma glucose concentration and/or increasing insulin sensitivity. | 2014-05-08 |
20140127167 | ANTIFUNGAL MIXTURE WITH FUNGAL ORGANISM PYTHIUM OLIGANDRUM - The antifungal mixture is designed for fighting human diseases and animal diseases of fungal, bacterial or other origin and for violation of bio-films on heterogeneous materials used both in human and veterinary medicine and for elimination of microflora from various objects coming in contact with humans or animals. The antifungal mixture uses the active component of the fungal organism | 2014-05-08 |
20140127168 | Polypeptide - The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application. | 2014-05-08 |
20140127169 | INDUCED PRESOMITIC MESODERM (IPSM) CELLS AND THEIR USE - The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues. | 2014-05-08 |
20140127170 | Method and Composition for Skin Grafts - A chimeric skin comprising immortalized human keratinocyte cells cocultured with donor keratinocytes is disclosed. | 2014-05-08 |
20140127171 | TREATMENT OF CHRONIC POST-TRAUMATIC ENCEPHALOPATHY - Methods of treating chronic post-traumatic encephalopathy (PTE) using regenerative approaches is described. In one embodiment, molecules with capability of stimulating endogenous neural stem cells is provided. In another embodiment, cell therapeutics are provided capable of addressing angiogenic deficits in patients suffering from PTE. In another embodiment, cells are utilized to induce activation of endogenous progenitor cells in the central nervous system of PTE patients. Furthermore, low level laser irradiation is disclosed as a means of treatment of PTE either through direct administration to CNS tissue for stimulation of endogenous progenitor cells and reparative processes, or together with administration of exogenous stem cells, whether autologous or allogeneic. In a further embodiment exogenous stem cells are pretreated with laser prior to administration. | 2014-05-08 |
20140127172 | METHODS OF PRESERVING FUNCTIONALITY OF AN ORGAN, PRESERVING FERTILITY OF A PATIENT UNDERGOING A TREATMENT EXPECTED TO CAUSE STERILITY AND ASSURING A SUPPLY OF VIABLE GAMETES FOR FUTURE USE - A method of preserving functionality of an organ is disclosed herein, including removing a whole organ including vasculature from a donor, cryo-preserving the whole organ including vasculature, thawing the whole organ including vasculature so that at least a portion of cells contained therein resume biological activity, and introducing the whole organ including vasculature into a recipient so that a blood vessel in the vasculature is supplied with blood. Further disclosed herein is a method of preserving fertility of a patient undergoing a treatment expected to cause sterility, including removing at least one whole gonadal organ including vasculature from the patient, preserving functionality of the gonadal organ as described herein, conducting the treatment and waiting for an effect thereof to subside, and introducing the gonadal organ into the patient. | 2014-05-08 |
20140127173 | POPULATIONS OF SMOOTH MUSCLE CELLS OF SPECIFIC EMBRYONIC LINEAGES - This invention relates to the production of populations of Smooth Muscle Cells (SMCs) of specific embryonic lineages, such as neuroectodermal and mesodermal SMCs. Pluripotent stem cells are cultured in one or more lineage induction media to produce progenitor cells of a defined embryonic lineage, which are then cultured in an SMC induction medium to produce a population of SMCs of the embryonic lineage. Populations of SMCs of defined lineages may be useful, for example, in in accurately modelling vascular disease. | 2014-05-08 |
20140127174 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2014-05-08 |
20140127175 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2014-05-08 |
20140127176 | ORAL BACTERIA AND USES THEREOF - The present invention relates to compositions and methods for preventing and treating periodontitis and other conditions. In particular, the present invention relates to oral bacteria for use in treating and preventing diseases and conditions. | 2014-05-08 |
20140127177 | Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 2014-05-08 |
20140127178 | METHODS AND COMPOSITIONS TO REDUCE ANIMAL WASTE PARAMETERS - The invention relates to the use of a microbial composition for the simultaneous reduction of important animal waste parameters, such as ammonia emission, the dry matter content, and amount of nitrogen, the amount of ammonium, and the amount of phosphorus present in the animal waste. It further relates to a method for the simultaneous reduction of important animal waste parameters, such as ammonia emission, the dry matter content, and amount of nitrogen, the amount of ammonium, and the amount of phosphorus present in the animal waste; comprising administering a microbial composition to an animal. | 2014-05-08 |
20140127179 | Natural Killer Cell Formulations - A formulation of supplement is able to boost the natural cells, both increasing the population of the natural cells and enhancing the natural cell's activity. The formulation can be administered via different forms, such as tablet, injection, skin absorption and etc. This formulation comprises 16 different components, including Alpha Lipoic Acid, Arabinoxylin, Curcumin, Garlic, Genistein, Ginseng, Lentinan, Mistletoe, N-Acetylcysteine, Resveratrol, Selenium, Vitamin B Complex, Vitamin C, Vitamin D3, Vitamin E and Zinc. By virtue of enhancing the natural killer cells (NKC) in the body, the formation is helpful for the prevention and treatment of a number of different human or animal diseases, such as cancers and viral infections. In addition, certain synergistic effects have been observed between different components in the formulation, which further enhances the beneficial effect of the formulation. | 2014-05-08 |
20140127180 | MUTANT CYTOCHROME P450 2B6 PROTEINS AND USES THEREOF - The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy. | 2014-05-08 |
20140127181 | Stabilised Compositions of Factor VII Polypeptides - The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature. | 2014-05-08 |
20140127182 | Using GNMT as a Novel Therapeutic or Preventing Agent for Fatty Liver Related Diseases - The present invention relates to a use of Glycine N-methyltransferase (GNMT) in treating or preventing fatty liver related disease, such as nonalcoholic fatty liver disease (NAFLD) or hepatocellular carcinoma (HCC). The use of GNMT for treating or preventing fatty liver diseases is achieved by enhancing GNMT-NPC2 interaction, and thus decreasing or preventing the accumulation of lipid and cholesterol in hepatic cells or tissues. | 2014-05-08 |
20140127183 | HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS - Methods of enhancing angiogenesis utilizing carboxy-terminal truncated human tyrosyl-tRNA synthetase (TyrRS) are disclosed. The truncated human TyrRS polypeptides comprise residues 1-364 or residues 1-343 of full length human TyrRS (SEQ ID NO: 2). | 2014-05-08 |
20140127184 | COMPOUNDS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS - Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder. | 2014-05-08 |
20140127185 | METHODS AND COMPOSITIONS USING NEUROPROTECTIVE STEROIDS AND THROMBOLYTIC AGENTS - Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as progesterone or allopregnanolone, and a thrombolytic agent, such as tissue plasminogen activator (tPA). Also described are compositions and methods for reducing the risks of thrombolytic agent treatment using a neuroprotective steroid. | 2014-05-08 |
20140127186 | PHARMACEUTICAL COMPOSITION FOR TREATING SCARS ON THE SKIN, AND METHOD FOR TREATING SCARS ON THE SKIN USING SAME - The present invention relates to a pharmaceutical composition for treating scars on the skin, comprising a mixture of botulinum toxin and air. The mixture of botulinum toxin and air according to the present invention, when injected in the dermis, may temporarily removed the elasticity of the dermis and flatten out the depressed part of the scar, and thus enables elaborate intradermic resection and increases the therapeutic effects of lasers for treating pulsed dye laser or of fractional lasers. Thus, scars on the skin can be effectively improved through a one-time operation without negatively affecting the daily lives of patients. | 2014-05-08 |
20140127187 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST - Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anti cancer-associated fibroblast composition; and a method for treatment of cancer. | 2014-05-08 |
20140127188 | METHOD FOR TREATMENT OF ADIPOSE DEPOSITS - Embodiments of the invention include methods and compositions for treatment of adipose deposits. | 2014-05-08 |
20140127189 | COMPOSITION FOR PREVENTING OR ALLEVIATING SKIN WRINKLES CONTAINING HONEYBUSH EXTRACT OR FERMENTED HONEYBUSH AS AN ACTIVE INGREDIENT - Provided is a composition for preventing or alleviating skin wrinkles containing honeybush ( | 2014-05-08 |
20140127190 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES - Described herein are peptides from secretory phospholipase A | 2014-05-08 |
20140127191 | ANTI-ABETA GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES - Anti-Aβ globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. | 2014-05-08 |
20140127192 | METHOD FOR TREATING OSTEOPOROSIS - The invention is directed to a method for increasing bone mineral density (BMD) in a postmenopausal woman. The method comprises administering to a postmenopausal woman having a lumbar vertebrae T-score of less than or equal to −2 an anti-sclerostin antibody in an amount and for a time effective to increase lumbar vertebrae BMD at least about 9% from pretreatment baseline at twelve months following initial anti-sclerostin antibody administration. The invention also is directed to a method for treating osteoporosis. The method comprising administering to a postmenopausal woman with osteoporosis an anti-sclerostin antibody in an amount of about 70 mg to about 210 mg at once a month, optionally for about three to about 18 months. Alternatively, the method comprises administering an anti-sclerostin antibody in an amount of about 140 mg to about 210 mg every three months, optionally about six to about 18 months. | 2014-05-08 |
20140127193 | METHODS OF DEVELOPING A PROGNOSIS FOR PANCREATIC CANCER AND PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS - Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer. | 2014-05-08 |
20140127194 | COMBINED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS - The invention relates to the use deuterium depleted water (DDW) for the preparation of combined pharmaceutical compositions for the prevention or treatment of tumorous diseases, where the composition comprises DDW with deuterium content of 0.01 to 135 ppm and one or more antineoplastic agent(s), optionally together with one or more usual pharmaceutical auxiliary material(s). Further, the invention relates to pharmaceutical compositions for adjuvant treatment of tumorous diseases, where the composition comprises DDW with deuterium content of 0.01 to 135 ppm and one or more antineoplastic agent(s), optionally together with one or more usual pharmaceutical auxiliary material(s). The invention also relates to aqueous pharmaceutical compositions usually applied in curing where the aqueous component is DDW with deuterium content of 0.01 to 135 ppm. | 2014-05-08 |
20140127195 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM ISCHEMIC OR HEMORRHAGIC INJURY USING ANTI ALPHA4 INTEGRIN ANTAGONISTS - Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described. | 2014-05-08 |
20140127196 | Anti-Complement C1s Antibodies and Uses Thereof - The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions. | 2014-05-08 |
20140127197 | Anti-CD22 Antibodies and Immunoconjugates and Methods of Use - Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided. | 2014-05-08 |
20140127198 | Antigen Presenting Cell Targeted Anti-Viral Vaccines - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2014-05-08 |
20140127199 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS - The invention features compositions comprising agents that inhibit or reduce self-reactive IgE and/or basophils, and related methods of using the compositions for treating or preventing lupus, lupus nephritis, and lupus-related disorders. | 2014-05-08 |
20140127200 | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 2014-05-08 |
20140127201 | COMPOSITIONS AND METHODS RELATED TO GRAFT VERSUS HOST DISEASE AND TREATMENTS THEREOF - Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities. | 2014-05-08 |
20140127202 | ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN - Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases. | 2014-05-08 |
20140127203 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS EFFECTOR FUNCTION - Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition. | 2014-05-08 |
20140127204 | ANTI-PROPERDIN ANTIBODIES - A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject. | 2014-05-08 |
20140127205 | Synthetic scFv Analogue To The 6313/G2 (Anti Angiotensin II Type 1 Receptor) Monoclonal Antibody Variable Regions - The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto. | 2014-05-08 |
20140127206 | METHODS OF TREATING PAIN USING AN IL-31 MONOCLONAL ANTIBODY - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2014-05-08 |
20140127207 | ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF - Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed. | 2014-05-08 |
20140127208 | Anti-Complement C1s Antibodies and Uses Thereof - The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions. | 2014-05-08 |
20140127209 | ANTIBODY DERIVATIVES - The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies. | 2014-05-08 |
20140127210 | BISPECIFIC ANTIGEN BINDING PROTEIN COMPLEX AND PREPARATION METHODS OF BISPECIFIC ANTIBODIES - A bispecific antigen binding protein complex comprising a first polypeptide comprising a first antigen binding site at an N terminus; a second polypeptide comprising a second antigen binding site at an N terminus; and a linker connecting the first polypeptide and the second polypeptide; wherein the linker comprises a tag at one terminus thereof, and wherein the tag is connected to a C-terminus of the first polypeptide or to an N-terminus of the second polypeptide, and comprises a cleavable amino acid sequence; as well as related compositions and methods. | 2014-05-08 |
20140127211 | ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES - The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same. | 2014-05-08 |
20140127212 | Binding Members For IgE Molecules - This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma. | 2014-05-08 |
20140127213 | GENETIC POLYMORPHISMS ASSOCIATED WITH AUTOINFLAMMATORY DISEASES, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoinflammatory diseases such as psoriasis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 2014-05-08 |
20140127214 | NATURAL IGM ANTIBODIES AND INHIBITORS THEREOF - The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders. | 2014-05-08 |
20140127215 | CLOSTRIDIUM DIFFICILE ANTIGENS - Compositions and methods for the treatment or prevention of | 2014-05-08 |
20140127216 | NOVEL EXPRESSION CASSETTE FOR EFFICIENT SURFACE DISPLAY OF ANTIGENIC PROTEINS - An expression cassette, wherein said expression cassette comprises: (a) an ie 1 promoter from white spot syndrome virus or a variant thereof; (b) a nucleic acid sequence encoding an N-terminal gp64 signal peptide or variant thereof, a nucleic acid sequence encoding an antigenic peptide, a nucleic acid encoding a transmembrane region, and a nucleic acid encoding a gp64 cytoplasmic region or variant thereof; in which the promoter is operably linked to the nucleic acid sequence. | 2014-05-08 |
20140127217 | PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST CANDIDIASIS | 2014-05-08 |
20140127218 | PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST CANDIDIASIS | 2014-05-08 |
20140127219 | ANTIBODIES FOR TREATMENT OF CANCER - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer. | 2014-05-08 |
20140127220 | INTERLEUKIN-10 PEPTIDES AND ANTIBODIES THEREOF FOR INHIBITING ADVERSE EFFECTS OF PROTOZOAN INFECTION - The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals. | 2014-05-08 |
20140127221 | Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae - The invention relates to the polynucleotide sequence of a nontypeable strain of | 2014-05-08 |
20140127222 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2014-05-08 |
20140127223 | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE SIGMA ANTIBODY - A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase σ (human PTPRS), or a fragment including an antigen-binding region thereof. | 2014-05-08 |
20140127224 | Therapeutic Method - Described herein are methods for treating connective tissue growth factor (CTGF)-associated cancers, including pancreatic cancer, using an anti-CTGF antibody. Increased antibody exposure was demonstrated to improve patient outcome. | 2014-05-08 |
20140127225 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF PROTEIN AGGREGATION INVOLVING IC3B DEPOSITION - The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment. | 2014-05-08 |
20140127226 | T Cell Regulation - Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity. | 2014-05-08 |
20140127227 | PROTEIN FORMULATIONS CONTAINING AMINO ACIDS - Provided are stable protein formulations that contain at least one amino acid. In certain embodiments, amino acid combinations either at least two, or three, or four, or more amino acids are included. By virtue of inclusion of the amino acids, the formulation has low viscosity and a protein in the formulations is physically, chemically, and biological stable even at high concentrations. In further embodiments, by virtue of inclusion of the amino acids, a protein in the formulations is physically, chemically, and biological stable even at high concentrations. | 2014-05-08 |
20140127228 | INHIBITION OF TGFBETA SIGNALING TO IMPROVE MUSCLE FUNCTION IN CANCER - Methods and compositions useful for the treatment and/or prevention of muscle weakness in cancer patients. In certain embodiments, the methods of the present invention include administering to a cancer patient a therapeutically or prophylactically effective amount of one or more inhibitors of TGFbeta signaling. | 2014-05-08 |
20140127229 | IP-10 ANTIBODY DOSAGE ESCALATION REGIMENS - In certain embodiments, the present invention provides a method of treating an IP-10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100. | 2014-05-08 |
20140127230 | ANTIBODIES TO TGF-BETA - The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). | 2014-05-08 |
20140127231 | p38 MAPK Pathway Inhibitors as Female-Specific Therapeutics - The present invention provides compositions and methods for preventing and treating a disorder, including, for example, an autoimmune disorder (e.g. multiple sclerosis), neuroinflammation, a neurodegenerative disease, or a behavioral disorder. In one embodiment, the present invention includes administering a p38 MAPK inhibitor to a female subject in order to treat or prevent an autoimmune disorder. In another embodiment, the invention provides administering a p38 MAPK inhibitor to a specific cell population. | 2014-05-08 |
20140127232 | DETECTING, PREVENTING, AND TREATING BRONCHOPULMONARY DYSPLASIA - Provided herein are methods for preventing or treating bronchopulmonary dysplasia (BPD) in a subject. The methods comprise identifying connective tissue mast cells (CTMCs) in a subject and administering an agent that blocks an activity of blocks an increase in a level of or reduces a level of the CTMCs in the subject. Also provided are methods of identifying a subject with or at risk for developing BPD. Also provided are methods for determining the effectiveness of a treatment regime for BPD in a subject. | 2014-05-08 |
20140127233 | PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC EVENTS - Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed. | 2014-05-08 |
20140127234 | Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof - The present invention relates to novel agents that are useful for treating hormone-dependent disorders. In particular, the present invention relates to A method of modulating a nuclear receptor in vivo comprising the step of administering to a subject in need thereof nuclear receptor modulating agent comprising a compound or composition capable of altering the endogenous levels of HLS-5 or its activity. | 2014-05-08 |
20140127235 | TARGETING HK alpha FOR CONTROLLING BLOOD PRESSURE AND REGULATING ELECTROLYTE BALANCE - Disclosed herein are novel methods for controlling blood pressure that involve targeting HK alpha. Also, disclosed are novel compositions for treating elevated blood pressure that include administering an agent that disrupts HK alpha expression or activity. Methods of screening novel antihypertensives are disclosed as well. | 2014-05-08 |
20140127236 | HUMANISED ANTI-CD52 ANTIBODIES - The present invention relates to novel humanised antibodies against human CD52 and their use in methods of treating or preventing human diseases. | 2014-05-08 |
20140127237 | Anti-Mesothelin Antibodies - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments. | 2014-05-08 |
20140127238 | METHODS, SYSTEMS AND PRODUCTS FOR PREDICTING RESPONSE OF TUMOR CELLS TO A THERAPEUTIC AGENT AND TREATING A PATIENT ACCORDING TO THE PREDICTED RESPONSE - The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided. | 2014-05-08 |
20140127239 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A compound which is either A: | 2014-05-08 |
20140127240 | Novel Binder-Drug Conjugates (ADCs) and Use of Same - The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures. | 2014-05-08 |
20140127241 | ANTIBODY/DRUG CONJUGATES AND METHODS OF USE - The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target. | 2014-05-08 |
20140127242 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN - The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2014-05-08 |
20140127243 | PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST CANDIDIASIS | 2014-05-08 |
20140127244 | VACCINES FOR SUPPRESSING IGE-MEDIATED ALLERGIC DISEASE AND METHODS FOR USING THE SAME - Nucleic acid molecules that encode a protein comprising at least one epitope of membrane IgE free of epitopes present on the serum IgE, including proteins that further comprise non-IgE T cell helper epitope are disclosed. Vaccines, vectors and host cells that comprise such nucleic acid molecules are disclosed. Isolated proteins, including haptenized proteins, comprising at least one epitope of membrane IgE free of epitopes present on the serum IgE, including proteins that further comprise non-IgE T cell helper epitope are disclosed. Vaccines that comprise and methods of making such proteins and antibodies that specifically bind to such proteins are disclosed. Vaccines that comprise killed or inactivated cells or particles are disclosed. Methods of treating and preventing IgE mediated allergic disease or condition are disclosed. | 2014-05-08 |
20140127245 | Small Peptides And Methods For Treatment Of Chronic Obstructive Pulmonary Disease - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 2014-05-08 |
20140127246 | SPANX-B POLYPEPTIDES AND THEIR USE - It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4 | 2014-05-08 |
20140127247 | VACCINES FOR HSV-2 - Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects. | 2014-05-08 |
20140127248 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA - Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 2014-05-08 |
20140127249 | INFLUENZA VIRUS MUTANTS AND USES THEREFOR - Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination. | 2014-05-08 |
20140127250 | STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS - The invention provides proteins from | 2014-05-08 |
20140127251 | VACCINES FOR PREVENTION AND TREATMENT OF TUBERCULOSIS - The present invention provides new immunological compositions and vaccines comprising selected | 2014-05-08 |
20140127252 | TULAREMIA-TAA/CD40L VACCINE - A Tularemia vaccine proposes to induce antibodies which through their binding to the target proteins of the vaccine strategy will inactivate the proteins essential to mediating the secretory function of the pilus proteins of the “type IV pilus proteins” or Tfp proteins, thereby impairing the formation of the pilus proteins on the surface of the FT which are needed for binding and entry of the FT into macrophages, and will inhibit the secretion of several factors of FT which are necessary for the virulence of the FT, and which are missing in attenuated strains of FT used in current attenuate strain vaccination strategies. The vaccine may be a mixture of DNA plasmids encoding TAA/ecdCD4OL protein vaccines in which the TAA is comprised of fragments of the following Tularemia proteins: Tfp, pilA, pilC, pilT, and pilQ, | 2014-05-08 |
20140127253 | BIODEGRADABLE PARTICULATE FORMULATIONS - The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant. | 2014-05-08 |
20140127254 | TRANSGENIC ALGAE FOR DELIVERING ANTIGENS TO AN ANIMAL - Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter. In one illustrated embodiment, the biologically active protein is an antigenic epitope and upon administration to the animal the algal cell induces an immune response in the host animal. | 2014-05-08 |
20140127255 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 2014-05-08 |
20140127256 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING LIVER FIBROSIS OR NONALCOHOLIC FATTY LIVER DISEASE - The present invention provides a pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease, comprising 50 to 90% by weight of | 2014-05-08 |
20140127257 | DERMATOLOGICALLY EFFECTIVE YEAST EXTRACT - The invention relates to a method for producing a dermatologically active yeast extract, comprising the following steps: providing a preculture of the yeast cells, culturing the cells for at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and products comprising said yeast extract. | 2014-05-08 |
20140127258 | Viral Vector Immunogenic Compositions - There is provided a composition comprising: (a) a modified vaccinia virus ankara (MVA) vector, wherein said MVA vector comprises a nucleic acid sequence encoding an antigen; and (b) an adjuvant comprising a saponin, or an emulsion. There is also provided a composition comprising: (a) an adenovirus vector, wherein said adenovirus vector comprises a nucleic acid sequence encoding an antigen, and wherein the adenovirus is selected from: a group B adenovirus, a group C adenovirus, and a group E adenovirus; and (b) an adjuvant comprising a saponin, or an emulsion; wherein the group B adenovirus is not an adenovirus 35, the group C adenovirus is not Ad5 having an intact E3 gene region, and the group E adenovirus is not an adenovirus C7. Also provided are corresponding uses of the compositions in medicine. | 2014-05-08 |
20140127259 | COMPOSITIONS AND METHODS FOR VACCINATING CATTLE - The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against | 2014-05-08 |
20140127260 | HPV VACCINE FORMULATIONS COMPRISING ALUMINUM ADJUVANT AND METHODS OF PRODUCING SAME - The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided. | 2014-05-08 |
20140127261 | Flavivirus Envelope Protein Mutations Affecting Virion Disassembly - Mutations in the central monomer contact interface of the flavivirus envelope protein which modulate the infectivity of the flavivirus are made. The mutations decrease the ability of the envelope dimer protein to dissociate. | 2014-05-08 |
20140127262 | REFRIGERATOR-TEMPERATURE STABLE INFLUENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided. | 2014-05-08 |